Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.
Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary

STILNOX CR 12.5MG MODIFIED RELEASE TABLET [SIN13403P]

Active ingredients: (LAYER 1 & 2) ZOLPIDEM TARTRATE

View product's general information
Last updated on 9 October 2026

Product Info

STILNOX CR 12.5MG MODIFIED RELEASE TABLET

[SIN13403P]

Product information

Active Ingredient and Strength

(LAYER 1 & 2) ZOLPIDEM TARTRATE - 6 MG & 6.5 MG

Dosage Form

TABLET, MULTILAYER, EXTENDED RELEASE

Manufacturer and Country

SANOFI WINTHROP INDUSTRIE - FRANCE

Registration Number

SIN13403P

Licence Holder

SANOFI-AVENTIS SINGAPORE PTE. LTD.

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

N05CF02

Prescription-only Medicines with Exemptions for Supply without Prescription

NA

Indication

INDICATIONS

STILNOX CR is indicated for the short-term treatment of insomnia in adults (see DOSAGE AND ADMINISTRATION).

Dosing

DOSAGE AND ADMINISTRATION

The treatment should always be implemented at the lowest effective dose, and the maximum dosage should never be exceeded.

STILNOX CR acts rapidly and should therefore be taken immediately before retiring. As with all hypnotics, long-term use is not recommended and a course of treatment should not exceed four weeks.

The effect of Stilnox CR may be slowed by ingestion with or immediately after a meal.
The lowest effective daily dose of zolpidem should be used and must not exceed 12.5 mg.

As with all hypnotics, long-term use of zolpidem is not recommended. Treatment should be as short as possible and should not exceed four weeks. Extension beyond the maximum treatment period should not take place without re-evaluation of the patient’s status, since the risk of abuse and dependence increases with the duration of treatment.

Discontinuation of treatment: see ADVERSE REACTION section – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.

Withdrawal Effects: see PRECAUTIONS – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.

Recommended Dosage:

Tablets should not be divided, crushed or chewed.

Adults
The recommended daily dose is 12.5 mg.

Elderly or Debilitated Patients
The recommended daily dose is 6.25 mg.

Hepatic Impairment
The recommended daily dose is 6.25 mg and these patients should be closely monitored. STILNOX CR should not be used in patients with severe hepatic impairment (see CONTRAINDICATIONS).

Renal impairment
No dosage adjustment is necessary in these patients, although they should be closely monitored.

Children
As the safety and efficacy of STILNOX CR has not yet been established, the use of STILNOX CR in children under 18 years of age is contra-indicated.

Contraindications

CONTRAINDICATIONS

Zolpidem is contraindicated in patients

  • With a hypersensitivity to zolpidem or any of the inactive ingredients,

  • With severe hepatic insufficiency,

  • With acute and/or severe respiratory insufficiency,

  • Who have previously experienced complex sleep behaviors after taking STILNOX CR,

  • Who have myasthenia,

  • Who have sleep apnea syndrome.

Due to lactose content, this medicinal product is contraindicated in the event of congenital galactosaemia, glucose or galactose malabsorption syndrome or lactase deficiency.

STILNOX CR should not be prescribed for children under 18 years of age.